Supreme Court Denies Martin Shkreli's Appeal Over $64 Million Penalty

The decision upholds penalties for Shkreli's role in inflating a lifesaving drug's price and bans him from the pharmaceutical industry.

The U.S. Supreme Court refused to hear Martin Shkreli's appeal against a $64.6 million financial penalty, reaffirming a lower court's decision.
Shkreli's former company, Turing Pharmaceuticals, raised the price of the drug Daraprim from $13.50 to $750 per pill in 2015.
The court's decision also maintains a lifetime ban on Shkreli from the pharmaceutical sector, imposed for anticompetitive practices.
Shkreli argued that the profits were retained by his company, but prosecutors held him accountable as the mastermind behind the scheme.
The ruling includes the forfeiture of the Wu-Tang Clan's rare album, 'Once Upon a Time in Shaolin,' which Shkreli previously purchased.